Recruiting NCT06717594

PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE

Trial Parameters

Condition Gram Negative Infections

Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna

Study Type OBSERVATIONAL

Phase N/A

Enrollment 60

Sex ALL

Min Age 18 Years

Max Age N/A

Start Date 2023-12-01

Completion 2026-04-30

All Conditions

Gram Negative Infections Antimicrobial Resistance (AMR)

Brief Summary

A multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime/avibactam (CAZ/AVI) alone or with CAZ/AVI plus fosfomycin (FOS) for infection due to carbapenem-resistant Enterobacterales (CRE) (KPC and/or OXA-48).

Eligibility Criteria

Inclusion Criteria: * Signature of the informed consent * Age ≥ 18 years * Adult patients treated for ≥ 48 hours with CAZ/AVI or CAZ/AVI plus FOS for a microbiologically documented CRE infection Exclusion Criteria: * Polymicrobial/mixed infections with exception of cases with multiple Enterobacterales susceptible to study drugs

Related Trials

NCT07491419

The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Ou

View Trial →

NCT06717594

PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE GRAM NEGATIVE INFECTIONS TRIALS